Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size, Status and Forecast 2019-2025

Description:
Attention Deficit Hyperactivity Disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. It may begin in early childhood and can continue into adulthood. Without treatment, ADHD can cause problems at home, at school, at work, and with relationships. In the past, ADHD was termed as Attention Deficit Disorder (ADD). The exact cause is not known, but ADHD tends to run in families. Boys are about three times more likely than girls to be diagnosed with it.

For many people, ADHD medications reduce hyperactivity and impulsivity and improve their ability to focus, work, and learn. On the basis of medication the market size covers Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexamfetamine, and Lisdexamfetamine Dimesylate): Stimulant is the most common type of medication used for treating ADHD. It increases the brain chemicals dopamine and norepinephrine, which play important roles in thinking and attention; Non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine): These medications take longer to start working than stimulants, but can also improve focus, attention, and impulsivity in a person with ADHD. Although not approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of ADHD, some antidepressants are sometimes used alone or in combination with a stimulant to treat ADHD.

In 2018, the global Attention Deficit Hyperactivity Disorder (ADHD) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Attention Deficit Hyperactivity Disorder (ADHD) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Attention Deficit Hyperactivity Disorder (ADHD) development in United States, Europe and China.

The key players covered in this study
- Shire
- Neos Therapeutics
- Eli Lilly
- Pfizer
- Alcobra
- Supernus Pharmaceuticals
- Noven Pharmaceuticals
- Novartis
- Johnson & Johnson
- Curemark

Market segment by Type, the product can be split into
- Stimulants
- Non-Stimulants

Market segment by Application, split into
- Specialty Clinics
- Hospital
- Retail

Market segment by Regions/Countries, this report covers
- United States
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America

The study objectives of this report are:
- To analyze global Attention Deficit Hyperactivity Disorder (ADHD) status, future forecast, growth opportunity, key market and key players.
- To present the Attention Deficit Hyperactivity Disorder (ADHD) development in United States, Europe and China.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Attention Deficit Hyperactivity Disorder (ADHD) are as follows:
- History Year: 2014-2018
- Base Year: 2018
- Estimated Year: 2019
- Forecast Year 2019 to 2025

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate by Type (2014-2025)
1.4.2 Stimulants
1.4.3 Non-Stimulants
1.5 Market by Application
1.5.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Application (2014-2025)
1.5.2 Specialty Clinics
1.5.3 Hospital
1.5.4 Retail
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Attention Deficit Hyperactivity Disorder (ADHD) Market Size
2.2 Attention Deficit Hyperactivity Disorder (ADHD) Growth Trends by Regions
2.2.1 Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Regions (2014-2025)
2.2.2 Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Manufacturers
3.1.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Manufacturers (2014-2019)
3.1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Concentration Ratio (CR5 and HHI)
3.2 Attention Deficit Hyperactivity Disorder (ADHD) Key Players Head office and Area Served
3.3 Key Players Attention Deficit Hyperactivity Disorder (ADHD) Product/Solution/Service
3.4 Date of Enter into Attention Deficit Hyperactivity Disorder (ADHD) Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2014-2019)

5 United States
5.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Market Size (2014-2019)
5.2 Attention Deficit Hyperactivity Disorder (ADHD) Key Players in United States
5.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type
5.4 United States Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Application

6 Europe
6.2 Attention Deficit Hyperactivity Disorder (ADHD) Key Players in Europe
6.3 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type
6.4 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Application

7 China
7.1 China Attention Deficit Hyperactivity Disorder (ADHD) Market Size (2014-2019)
7.2 Attention Deficit Hyperactivity Disorder (ADHD) Key Players in China
7.3 China Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type
7.4 China Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Application

8 Japan
8.1 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Size (2014-2019)
8.2 Attention Deficit Hyperactivity Disorder (ADHD) Key Players in Japan
8.3 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type
8.4 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Market Size (2014-2019)
9.2 Attention Deficit Hyperactivity Disorder (ADHD) Key Players in Southeast Asia
9.3 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type
9.4 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Application

10 India
10.1 India Attention Deficit Hyperactivity Disorder (ADHD) Market Size (2014-2019)
10.2 Attention Deficit Hyperactivity Disorder (ADHD) Key Players in India
10.3 India Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type
10.4 India Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Application

11 Central & South America
11.1 Central & South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size (2014-2019)
11.2 Attention Deficit Hyperactivity Disorder (ADHD) Key Players in Central & South America
11.3 Central & South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type
11.4 Central & South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Application

12 International Players Profiles
12.1 Shire
12.1.1 Shire Company Details
12.1.2 Shire Description and Business Overview
12.1.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
12.1.4 Shire Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
12.1.5 Shire Recent Development

12.2 Neos Therapeutics
- 12.2.1 Neos Therapeutics Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.2.4 Neos Therapeutics Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.2.5 Neos Therapeutics Recent Development

12.3 Eli Lilly
- 12.3.1 Eli Lilly Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.3.4 Eli Lilly Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.3.5 Eli Lilly Recent Development

12.4 Pfizer
- 12.4.1 Pfizer Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.4.4 Pfizer Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.4.5 Pfizer Recent Development

12.5 Alcobra
- 12.5.1 Alcobra Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.5.4 Alcobra Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.5.5 Alcobra Recent Development

12.6 Supernus Pharmaceuticals
- 12.6.1 Supernus Pharmaceuticals Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.6.4 Supernus Pharmaceuticals Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.6.5 Supernus Pharmaceuticals Recent Development

12.7 Noven Pharmaceuticals
- 12.7.1 Noven Pharmaceuticals Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.7.4 Noven Pharmaceuticals Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.7.5 Noven Pharmaceuticals Recent Development

12.8 Novartis
- 12.8.1 Novartis Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.8.4 Novartis Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.8.5 Novartis Recent Development

12.9 Johnson & Johnson
- 12.9.1 Johnson & Johnson Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.9.4 Johnson & Johnson Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.9.5 Johnson & Johnson Recent Development

12.10 Curemark
- 12.10.1 Curemark Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Attention Deficit Hyperactivity Disorder (ADHD) Introduction
- 12.10.4 Curemark Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2014-2019)
- 12.10.5 Curemark Recent Development

13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
- 15.1 Research Methodology
  - 15.1.1 Methodology/Research Approach
    - 15.1.1.1 Research Programs/Design
    - 15.1.1.2 Market Size Estimation
    - 12.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
  - 15.1.2.1 Secondary Sources
  - 15.1.2.2 Primary Sources
- 15.2 Disclaimer